An Open Label Randomized Crossover Study to Assess the Pharmacokinetic and Pharmacodynamic Profiles of Once Daily and Twice Daily Dose Regimens of Recombinant human Parathyroid Hormone

Grants and Contracts Details

StatusFinished
Effective start/end date10/19/179/12/19

Funding

  • Shire Development Inc: $65,132.00